Combined Screening (Delfia) with Hemoglobinopathy+HBA1C

Combined Screening (Delfia) with Hemoglobinopathy + HbA1c

Combined Screening (Delfia) with Hemoglobinopathy + HbA1c is an advanced prenatal and blood health screening test designed to assess fetal chromosomal risk along with inherited blood disorders and long-term blood sugar status. This comprehensive panel supports early pregnancy evaluation and maternal health monitoring.

What This Test Includes

• Combined Screening (Delfia):
  Evaluates the risk of chromosomal abnormalities such as:
  • Down Syndrome (Trisomy 21)
  • Edwards Syndrome (Trisomy 18)
  • Patau Syndrome (Trisomy 13)
• Hemoglobinopathy Screening:
  Detects inherited blood disorders including:
  • Thalassemia
  • Sickle Cell Disease
  • Other abnormal hemoglobin variants
• HbA1c Test:
  Measures average blood glucose levels over the past 2–3 months to assess:
  • Diabetes
  • Prediabetes
  • Glycemic control during pregnancy

Sample Required

• Maternal Blood Sample

Recommended For

• Pregnant women during the first trimester
• Individuals with a family history of blood disorders
• Patients requiring diabetes assessment during pregnancy

Benefits

• Early prenatal risk assessment
• Identification of inherited blood disorders
• Monitoring maternal glucose control
• Supports timely clinical decision-making

Reporting

• Accurate and reliable testing using advanced DELFIA technology
• Processed by experienced laboratory professionals

#CombinedScreening #Delfia #Hemoglobinopathy #HbA1c #PrenatalScreening #PregnancyCare #BiocareLaboratories #DiagnosticCare #MaternalHealth #BloodDisorderScreening #DiabetesScreening #Dermafact #gynofact